The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants

Journal of Psychopharmacology

Volumn 30, Issue 1, 2016, Pages 13-22

  Köhler, Stephan ^a   Cierpinsky, Katharina ^a   Kronenberg, Golo ^a   Adli, Mazda ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Department of Child and Adolescent Psychiatry Psychosomatic Medicine and Psychotherapy   (Germany)

Author keywords

depression; drug targets; novel antidepressants; Serotonin receptors

Indexed keywords

MILNACIPRAN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 5 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; VILAZODONE; VORTIOXETINE; ANTIDEPRESSANT AGENT; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER;

ALERTNESS; ANTIDEPRESSANT ACTIVITY; COGNITION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG RECEPTOR BINDING; EJACULATION DISORDER; ENZYME ACTIVATION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FATIGUE; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HYPERHIDROSIS; IN VIVO STUDY; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; NONHUMAN; NUMBERS NEEDED TO TREAT; OPEN STUDY; ORGASM DISORDER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SLEEP DISORDER; TACHYCARDIA; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; VOMITING; WEIGHT GAIN; WORKING MEMORY; ANIMAL; BRAIN; DEPRESSION; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSION; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPTIC TRANSMISSION;

EID: 84952018070     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115609072     Document Type: Review

References (86)

1. Alex KD, Yavanian GJ, Mcfarlane HG, et al. (2005) Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 55: 242-251.
2. Alvarez E, Perez V, Dragheim M, et al. (2012) A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 15: 589-600.
3. Auclair AL, Martel JC, Assie MB, et al. (2013) Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology 70: 338-347.
4. Baldwin D, Moreno RA, Briley M, (2008) Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Human Psychopharmacol 23: 527-532.
5. Baldwin DS, Hansen T, Florea I, (2012) Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 28: 1717-1724.
6. Baldwin DS, Loft H, Dragheim M, (2012) A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 22: 482-491.
7. Ban TA, (2008) Comment on: 'Antidepressant medications and other treatments of depressive disorders: a CINP task force report based on a review of evidence'. Int J Neuropsychopharmacol 11: 583-585; author reply 587-589.
8. Bhagwagar Z, Rabiner EA, Sargent PA, et al. (2004) Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 9: 386-392.
9. Billio A, Morello E, Clarke MJ, (2010) Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev CD006272.
10. Binder EB, Nemeroff CB, (2010) The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry 15: 574-588.
11. Boulenger JP, Loft H, Florea I, (2012) A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 26: 1408-1416.
12. Briley M, Moret C, (2010) Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors. Neuropsych Dis Treatment 6: 647-655.
13. Celada P, Bortolozzi A, Artigas F, (2013) Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 27: 703-716.
14. Citrome L, (2012) Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Practice 66: 356-368.
15. Citrome L, (2013) Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Practice 67: 1089-1104.
16. Clayton AH, Kennedy SH, Edwards JB, et al. (2013) The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sexual Med 10: 2465-2476.
17. Clayton AH, Pradko JF, Croft HA, et al. (2002) Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63: 357-366.
18. Dale E, Zhang H, Leiser SC, et al. (2014) Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. J Psychopharmacol 28: 891-902.
19. Dawson LA, Nguyen HQ, (1998) Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur J Pharmacol 345: 41-46.
20. Deardorff WJ, Grossberg GT, (2014) A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother 15: 2525-2542.
21. Egerton A, Ahmad R, Hirani E, et al. (2008) Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride pet studies in the rat. Psychopharmacology (Berl) 200: 487-496.
22. Fagiolini A, Comandini A, Catena Dell'Osso M, et al. (2012) Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs 26: 1033-1049.
23. Gelenberg AJ, Mcgahuey C, Laukes C, et al. (2000) Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 61: 356-360.
24. Goethe JW, Woolley SB, Cardoni AA, et al. (2007) Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J Clin Psychopharmacol 27: 451-458.
25. Guay DR, (2012) Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder. Consultant Pharmacist 27: 857-867.
26. Gudelsky GA, Yamamoto BK, (2008) Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 90: 198-207.
27. Halford JCG, Harrold JA, (2012) 5-HT2C receptor agonists and the control of appetite. In: Joost HG, (ed) Appetite Control. Berlin: Springer.
28. Hedlund PB, (2009) The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 206: 345-354.
29. Hull EM, Muschamp JW, Sato S, (2004) Dopamine and serotonin: influences on male sexual behavior. Physiol Behav 83: 291-307.
30. Iranikhah M, Wensel TM, Thomason AR, (2012) Vilazodone for the treatment of major depressive disorder. Pharmacotherapy 32: 958-965.
31. Jain R, Mahableshwarkar AR, Jacobsen PL, et al. (2013) A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 16: 313-321.
32. Johnston MM, Rapoport AM, (2010) Triptans for the management of migraine. Drugs 70: 1505-1518.
33. Judd LL, (1998) A decade of antidepressant development: the SSRIs and beyond. J Affect Disord 51: 211-213.
34. Kasper S, Meshkat D, Kutzelnigg A, (2011) Improvement of the noradrenergic symptom cluster following treatment with milnacipran. Neuropsych Dis Treatment 7: 21-27.
35. Kasper S, Pletan Y, Solles A, et al. (1996) Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 11 (Suppl. 4): 35-39.
36. Katona C, Hansen T, Olsen CK, (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27: 215-223.
37. Kempermann G, Kronenberg G, (2003) Depressed new neurons-adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol Psychiatry 54: 499-503.
38. Kennett GA, Marcou M, Dourish CT, et al. (1987) Single administration of 5-HT1A agonists decreases 5-HT1A presynaptic, but not postsynaptic receptor-mediated responses: relationship to antidepressant-like action. Eur J Pharmacol 138: 53-60.
39. Kessler RC, Berglund P, Demler O, et al. (2003) The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 289: 3095-3105.
40. Khan A, Sambunaris A, Edwards J, et al. (2014) Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression. Int Clin Psychopharmacol 29: 86-92.
41. Köhler S, Arndt A, Sterzer P, et al. (2013) [Individualized treatment with antidepressants]. Fortschr Neurol-Psychiatrie 81: 104-116; quiz 117-108.
42. Kronenberg G, Gertz K, Heinz A, et al. (2014) Of mice and men: modelling post-stroke depression experimentally. Br J Pharmacol 171: 4673-4689.
43. Landolt HP, Wehrle R, (2009) Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci 29: 1795-1809.
44. Maes M, (2008) The cytokine hypothesis of depression: inflammation, oxidative and nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuroendocrinol Lett 29: 287-291.
45. Mago R, Mahajan R, Thase ME, (2014) Levomilnacipran: a newly approved drug for treatment of major depressive disorder. Exp Rev Clin Pharmacol 7: 137-145.
46. Masana M, Santana N, Artigas F, et al. (2012) Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review. Curr Topics Med Chem 12: 2357-2374.
47. Mawe GM, Hoffman JM, (2013) Serotonin signalling in the gut-functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 10: 473-486.
48. McCorvy JD, Roth BL, (2015) Structure and function of serotonin G protein-coupled receptors. Pharmacol Therapeut 150: 129-142.
49. McIntyre RS, Lophaven S, Olsen CK, (2014) A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 17: 1557-1567.
50. McManis PG, Talley NJ, (1997) Nausea and vomiting associated with selective serotonin reuptake inhibitors. CNS Drugs 8: 394-401.
51. Meltzer HY, (2012) Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol 212: 87-124.
52. Meneses A, Perez-Garcia G, Ponce-Lopez T, et al. (2011) 5-Ht6 receptor memory and amnesia: behavioral pharmacology-learning and memory processes. Int Rev Neurobiol 96: 27-47.
53. Meyer JH, Wilson AA, Sagrati S, et al. (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Amer J Psychiatry 161: 826-835.
54. Miller JM, Brennan KG, Ogden TR, et al. (2009) Elevated serotonin 1a binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology 34: 2275-2284.
55. Montejo AL, Llorca G, Izquierdo JA, et al. (2001) Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 62 (Suppl. 3): 10-21.
56. Moret C, Briley M, (2000) The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol 404: 1-12.
57. Mork A, Pehrson A, Brennum LT, et al. (2012) Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Therapeut 340: 666-675.
58. Morrissette DA, Stahl SM, (2014) Modulating the serotonin system in the treatment of major depressive disorder. CNS Spectrums 19 (Suppl. 1): 57-67; quiz 54-57, 68.
59. Murphy JA, Byrne GJ, (2012) Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder. J Affect Disord 139: 172-180.
60. Nutt DJ, (2008) Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 69 (Suppl. E1): 4-7.
61. Pae CU, Wang SM, Han C, et al. (2014) Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci 39: 140120.
62. Papakostas GI, Fava M, (2007) A meta-analysis of clinical trials comparing milnacipran, a serotonin-norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol 17: 32-36.
63. Parsey RV, Oquendo MA, Ogden RT, et al. (2006) Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 59: 106-113.
64. Prins J, Olivier B, Korte SM, (2011) Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opin Investig Drugs 20: 1107-1130.
65. Rajkumar R, Mahesh R, (2010) The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target? J Psychopharmacol 24: 455-469.
66. Reynolds GP, Hill MJ, Kirk SL, (2006) The 5-HT2C receptor and antipsychoticinduced weight gain-mechanisms and genetics. J Psychopharmacol 20: 15-18.
67. Roberts AJ, Hedlund PB, (2012) The 5-HT(7) receptor in learning and memory. Hippocampus 22: 762-771.
68. Ruf BM, Bhagwagar Z, (2009) The 5-HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets 10: 1118-1138.
69. Ruhe HG, Mason NS, Schene AH, (2007) Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12: 331-359.
70. Sanchez C, Asin KE, Artigas F, (2015) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Therapeut 145: 43-57.
71. Saraceni MM, Venci JV, Gandhi MA, (2013) Levomilnacipran (fetzima): a new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder. J Pharm Practice 27: 389-395.
72. Sargent PA, Kjaer KH, Bench CJ, et al. (2000) Brain serotonin1a receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57: 174-180.
73. Savitz JB, Drevets WC, (2013) Neuroreceptor imaging in depression. Neurobiol Dis 52: 49-65.
74. Scorza MC, Llado-Pelfort L, Oller S, et al. (2012) Preclinical and clinical characterization of the selective 5-HT(1A) receptor antagonist Du-125530 for antidepressant treatment. Br J Pharmacol 167: 1021-1034.
75. Scott LJ, (2014) Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder. CNS Drugs 28: 1071-1082.
76. Seth P, Gajendiran M, Ganguly DK, (1997) Desensitization of spinal 5-HT1A receptors to 8-OH-DPAT: an in vivo spinal reflex study. Neuroreport 8: 2489-2493.
77. Shimizu S, Mizuguchi Y, Ohno Y, (2013) Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions. CNS Neurol Disord Drug Targets 12: 861-869.
78. Shin A, Camilleri M, Kolar G, et al. (2014) Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Therapeut 39: 239-253.
79. Singh M, Schwartz TL, (2012) Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsych Dis Treatment 8: 123-130.
80. Snoeren EM, Veening JG, Olivier B, et al. (2014) Serotonin 1A receptors and sexual behavior in male rats: a review. Pharmacol Biochem Behav 121: 102-114.
81. Stahl SM, Lee-Zimmerman C, Cartwright S, et al. (2013) Serotonergic drugs for depression and beyond. Curr Drug Targets 14: 578-585.
82. Sullivan GM, Oquendo MA, Milak M, et al. (2015) Positron emission tomography quantification of serotonin(1A) receptor binding in suicide attempters with major depressive disorder. JAMA Psychiatry 72: 169-178.
83. Thomas DR, (2006) 5-HT5A receptors as a therapeutic target. Pharmacol Therapeut 111: 707-714.
84. Vidal R, Pilar-Cuellar F, Dos Anjos S, et al. (2011) New strategies in the development of antidepressants: towards the modulation of neuroplasticity pathways. Curr Pharmaceut Design 17: 521-533.
85. Voleti B, Duman RS, (2012) The roles of neurotrophic factor and Wnt signaling in depression. Clin Pharmacol Therapeut 91: 333-338.
86. Zohar J, Nutt DJ, Kupfer DJ, et al. (2014) A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol 24: 1005-1014.